• Publications
  • Influence
Pilot study of SGN-15 immunoconjugate with docetaxel as first line therapy for NSCLC with PET assessment of response
7299 Background: NSCLC cells express tumor antigens, including Lewis Υ (Ley). SGN-15 is a novel antibody-drug conjugate that delivers doxorubicin to cells expressing Ley and has synergistic activityExpand